1
Clinical Trials associated with Calf Pulmonary SurfactantOptimal Dose of Surfactant for Preterm Infants With Respiratory Distress Syndrome(RDS)
In preterm infants with neonatal respiratory distress syndrome (RDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal incidences of bronchopulmonary dysplasia(BPD) and/or death. But not all preterm infants with RDS can be beneficial. Otherwise, the international neonatal acute RDS (NARDS) collaborative group provides the first consensus definition for NARDS in 2017. And whether or not PS being beneficial in preterm infants with NARDS remains unknown.
100 Clinical Results associated with Calf Pulmonary Surfactant
100 Translational Medicine associated with Calf Pulmonary Surfactant
100 Patents (Medical) associated with Calf Pulmonary Surfactant
100 Deals associated with Calf Pulmonary Surfactant